The distribution of neurofilament immunoreactivity in the substantia nigra was examined by immunohistochemistry in five patients dying with Parkinson's disease and six control patients dying without neurological disease. In controls, pigmented neurons in the substantia nigra were intensively labelled by SMI32, a monoclonal antibody to non-phosphorylated neurofilament protein. 
W P Gai, J C Vickers, P C Blumbergs, W W Blessing Abstract The distribution of neurofilament immunoreactivity in the substantia nigra was examined by immunohistochemistry in five patients dying with Parkinson's disease and six control patients dying without neurological disease. In controls, pigmented neurons in the substantia nigra were intensively labelled by SMI32, a monoclonal antibody to non-phosphorylated neurofilament protein. In the substantia nigra from patients who had Parkinson's disease, there was a pronounced reduction of SMI32 labelling intensity in surviving pigmented neurons. By contrast, tyrosine hydroxylase inmmunoreactivity in surviving pigmented neurons was normal. SM132 labelling was normal in regions of the brainstem not affected by the neuropathological process of Parkinson's disease. Findings with either antibodies to phosphorylated neurofilament, or enzymatic dephosphorylation followed by SMI32 labelling, indicated that loss of SMI32 immunostaining in Parkinson's disease was not due to masking of the neurofilament epitopes by phosphorylation. Our results indicate that neurofilament proteins are particularly likely to be disrupted or destroyed by the neuropathological process of Parkinson's disease. Nevertheless, the normal appearance of tyrosine hydroxylase indicates that protein synthesising systems may be intact in surviving neurons. Loss of neurofilament immunoreactivity may prove a sensitive neuropathological marker for characterisation of degenerating neurons in Parkinson's disease. (7 Neurol Neurosurg Psychiatry 1994; 57:1039 -1046 The neuropathological hallmarks of many neurodegenerative diseases consist of filamentous inclusion bodies in subsets of neurons, reflecting a disruption of the normal cytoskeleton,l and possibly contributing to neuronal dysfunction and degeneration. The Lewy bodies that occur in idiopathic Parkinson's disease are composed principally of neurofilament proteins, suggesting possible abnormalities in the cytoskeleton of neurons in Parkinson's disease. [2] [3] [4] [5] [6] [7] [8] Lewy bodies in the perikaryon also contain phosphorylated neurofilament proteins normally present in the axonal compartment of neurons.37
Biochemical studies have confirmed that neurofilament proteins are a major constituent of the Lewy bodies found in the cortex of patients with diffuse Lewy body disease. 9 The neuronal content of particular neurofilament proteins seems to be highly regulated, as shown by the differential distribution of such proteins in particular subsets of neurons,'°0 1 and by the propensity of the neurofilaments to modification via various metabolic pathways. 
Analysis
For quantitative morphological analysis we used a computer image system as previously described. 17 Outlines of sections, major nuclei, and fibre bundles were mapped under 5 x magnification and used to match section levels between individual cases. Cells were counted under 250 x magnification. In both control and Parkinson's disease groups the substantia nigra was measured rostrocaudally approximately 9 5 (05) mm (mean (SD), control, n = 3; Parkinson's disease, n = 3), from the caudal portion of the subthalamic nucleus to the caudal limit of the trochlear nucleus. Both these nuclei contained characteristic SMI32 positive neurons.
The number of melanin pigmented neurons varies through the rostrocaudal substantia nigra. '8 In the present study cell counting was made in sections at three carefully defined rostrocaudal substantia nigra levels. The rostral section was at the rostral limit of the oculomotor nucleus and the medial geniculate nucleus. At this level, no subthalamic neurons were present. The middle section was at the level where the medial geniculate nucleus was best represented in SMI32 immunostained sections. At the middle level, the boundaries of the paranigral nucleus and the substantia nigra were separated by the fibre tracks of the oculomotor neurons. The caudal section was at the caudal border of the red nucleus and the trochlear nucleus, where the superior cerebellar peduncles just separate from the decussation and form isolated fibre bundles. The three section levels were approximately 3 mm apart, spanning the rostral two thirds of the substantia nigra. The caudal one third of the substantia nigra contains fewer pigmented neurons, and it is sometimes difficult to distinguish between these cells and pigmented cells of the A8 group. Sections from the caudal one third were examined, but not quantitatively analysed.
For three control cases (N10, N19, N21) and all Parkinson's disease cases, we also counted, at the middle level of the substantia nigra, the total number of pigmented or TH positive pigmented neurons in sections adjacent to the sections stained with SMI32. neuronal cell bodies and dendrites in particular midbrain nuclei including the substantia nigra, the superior colliculus, the oculomotor and the interstitial nuclei, and the red nucleus, consistent with the known cellular distribution of non-phosphorylated neurofila- Figure 3 summarises the distribution of pigmented neurons, positive or negative for SMI32 or TH, at three rostrocaudal substantia nigra levels in control cases. The SMI32 negative pigmented neurons were preferentially located in the dorsal substantia nigra. In addition, many SMI32 negative pigmented cells were seen in the paranigral nucleus and in the midline region (not shown in fig 3) . SMI32 positive neurons containing no visible melanin pigment were found in the pars reticulata of the substantia nigra. Figure 4 shows the distribution of pigmented neurons containing or lacking SMI32 or TH, mapped at three corresponding rostrocaudal substantia nigra levels from the brain of a patient with Parkinson's disease. By contrast with the normal nigra, pigmented neurons lacking SMI32-ir in Parkinson's disease were numerous and widespread, contrasting with the relatively rare occurrence of TH negative neurons. In normal controls, phosphatase treatment for three hours or overnight had no obvious effect on SMI32 perikaryal and dendritic staining, either in the substantia nigra, or in other SMI32 positive nuclei. After phosphatase treatment, however, numerous axons became immunoreactive for SMI32. This was expected as SMI32 reacts with non-phosphorylated neurofilaments. The stained axons included intra-axial fibres of the oculomotor tions of normal controls, with occasional positive cell bodies. Mesencephalic trigeminal neurons were consistently labelled by both antibodies. In cases of Parkinson's disease, the axonal staining was similar, but no antibody positive pigmented cells were seen in the substantia nigra. Some Lewy bodies were stained positively by these antibodies ( fig 2H) .
Discussion
In control brains the number of pigmented neurons at a given level of the substantia nigra was reasonably constant across subjects. About 95% of these pigmented neurons contained intense SMI32 immunoreactivity, in both perikarya and dendrites. 25 and this may interfere with SMI32 antibody binding, falsely suggesting absence of the protein. In the present study we obtained evidence that the neurofilament protein was indeed absent, rather than being present but phosphorylated, by using antibodies against phosphorylated neurofilaments. No immunohistochemical reaction product for phosphorylated neurofilament (SMI3 1 and SMI34 antibodies) was seen in perikarya in regions affected in Parkinson's disease, but axons traversing the substantia nigra region, including those of the oculomotor nerve, did contain phosphorylated neurofilaments. These axons become SMI32 positive after the sections were treated with phosphatase enzyme. These findings confirm that our methodology could detect phosphorylated neurofilaments if they were present in pigmented substantia nigra neurons or in the proximal axonal processes of these cells. Nevertheless, we acknowledge that our results still do not exclude the possibility that the neurofilaments are present in the Parkinson's disease neurons, but structurally altered by some other process. Some non-lysosomal proteases, such as calciumactivated neutral proteases (calpains), are very active towards neurofilaments.2627 The exposed neurofilament tails might be more accessible to these attacks, leading to the disappearance of immunohistochemical staining for both non-phosphorylated and phosphorylated forms. Global protein degradation is less likely, as TH proteins were well preserved in the pigmented neurons. Hill et al 28 A number of neurological diseases, apart from idiopathic Parkinson's disease, are accompanied by degeneration of substantia nigra neurons, including Steele-RichardsonOlszewski syndrome, striatonigral degeneration, and Alzheimer's disease.'234 Elucidation of neurofilament changes in these diseases may provide clues to the degeneration process in Parkinson's disease. During the present study, we examined one patient with pathologically documented Steele-RichardsonOlszewski syndrome. This patient had severe (70%) loss of pigmented neurons in the substantia nigra but the proportion of surviving pigmented neurons which were SMI32-positive (97%), was similar to controls.
In conclusion, in Parkinson's disease there is disruption, possibly absence, of neurofilaments in surviving pigmented neurons of the substantia nigra. By contrast, surviving neurons in Parkinson's disease contain normal immunoreactivity for transmitter-related proteins such as TH. In neuropathological studies, loss of SMI32 staining may be useful in characterising neurons that seem normal by conventional histopathological criteria. Apart from the substantia nigra, some pigmented or non-pigmented neuronal groups are also affected by the processes underlying Parkinson's disease pathology. These include the neurons in the midbrain ventral tegmental area, locus coeruleus, pedunculopontine tegmental nucleus, preganglionic dorsal motor vagal neurons, and catecholamine neurons in the pons and medulla.'5-" We are currently studying whether neurons in these regions contain neurofilaments, and whether these neurofilaments are altered in Parkinson's disease.
